See more : Plaza S.A. (MALLPLAZA.SN) Income Statement Analysis – Financial Results
Complete financial analysis of Incannex Healthcare Limited (IXHL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Incannex Healthcare Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Midnight Sun Mining Corp. (MDNGF) Income Statement Analysis – Financial Results
- Tata Motors Limited (TATAMOTORS.NS) Income Statement Analysis – Financial Results
- Sutter Gold Mining Inc. (SGMNF) Income Statement Analysis – Financial Results
- Ribbit LEAP, Ltd. (LEAP-UN) Income Statement Analysis – Financial Results
- Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ) Income Statement Analysis – Financial Results
Incannex Healthcare Limited (IXHL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.incannex.com.au
About Incannex Healthcare Limited
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.00K | 0.00 | 540.17K | 1.42M | 417.45K | 1.09K | 749.19K | 216.77K | 68.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 4.38K | 683.84K | 310.80K | 0.00 | 387.89K | 396.97K | 48.92K | 13.76K | 430.76K | 757.99K | 1.22M | 41.75K | 391.02K | 0.00 | 0.00 | 0.00 | 15.29K |
| Gross Profit | 12.00K | 0.00 | 535.79K | 739.07K | 106.65K | 1.09K | 361.30K | -180.20K | 19.38K | -13.76K | -430.76K | -757.99K | -1.22M | -41.75K | -391.02K | 0.00 | 0.00 | 0.00 | -15.29K |
| Gross Profit Ratio | 100.00% | 0.00% | 99.19% | 51.94% | 25.55% | 100.00% | 48.23% | -83.13% | 28.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 12.88M | 41.66M | 3.71M | 3.54M | 1.46M | 516.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 16.83M | 7.93M | 193.99K | 74.31K | 315.85K | 231.80K | 573.43K | 612.04K | 268.89K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 348.00K | 84.00K | 1.90M | 3.26M | 280.35K | 66.56K | 901.40K | 423.04K | 53.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.17M | 8.01M | 4.66M | 4.84M | 1.35M | 375.15K | 2.58M | 1.85M | 509.60K | 486.81K | 397.05K | 1.37M | 1.15M | 2.73M | 361.62K | 513.85K | 826.11K | 839.29K | 107.68K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.49K | -93.16K | -202.43K | -152.02K | -180.81K | 0.00 | -131.67K | -27.52K | -24.19K |
| Operating Expenses | 30.05M | 49.67M | 8.37M | 8.40M | 2.81M | 891.96K | 2.58M | 1.85M | 509.60K | 486.81K | 390.56K | 1.46M | 1.35M | 2.88M | 180.81K | 513.85K | 957.78K | 866.81K | 131.87K |
| Cost & Expenses | 30.05M | 49.67M | 8.38M | 9.09M | 3.12M | 891.96K | 2.97M | 2.24M | 558.53K | -500.57K | -821.32K | -2.22M | -2.57M | -2.92M | -571.82K | -639.67K | -999.62K | -875.38K | -147.16K |
| Interest Income | 206.00K | 244.01K | 4.55K | 2.00K | 3.05K | 1.11K | 2.36K | 6.53K | 424.25 | 3.18K | 16.34K | 122.80K | 126.22K | 99.59K | 32.62K | 6.91K | 224.50K | 44.01K | 1.18K |
| Interest Expense | 0.00 | 3.01K | 218.07 | -10.46 | -89.80 | 60.83K | 9.98K | 37.56K | 89.76 | 99.84K | 160.04K | 195.54K | 194.91K | 93.67K | 107.56K | 35.09K | 10.92K | 5.05K | 15.59K |
| Depreciation & Amortization | 103.00K | 23.00K | 7.84M | 7.64M | 28.91K | 29.95K | 42.33K | 23.27K | 11.93K | 13.76K | 36.25K | 29.41K | 42.58K | 41.75K | 45.15K | 41.29K | 41.84K | 8.56K | 340.77 |
| EBITDA | -18.50M | -13.62M | 0.00 | 0.00 | -2.59M | -861.46K | -2.22M | -2.03M | -490.22K | -2.09M | -12.10M | -13.22M | -3.27M | -4.43M | 2.38M | -2.79M | -932.05K | -820.09K | -163.01K |
| EBITDA Ratio | -154,200.00% | 0.00% | 0.00% | 0.00% | -619.34% | -79,012.56% | -295.87% | -935.19% | -717.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -30.04M | -49.67M | -7.84M | -7.66M | -2.70M | -890.87K | -2.22M | -2.03M | -490.22K | -500.57K | -821.32K | -2.22M | -2.57M | -2.92M | -571.82K | -639.67K | -999.62K | -875.38K | -147.16K |
| Operating Income Ratio | -250,341.67% | 0.00% | -1,450.78% | -538.64% | -646.62% | -81,709.63% | -295.87% | -935.19% | -717.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 11.61M | 857.00K | -2.45M | -863.45K | -12.42K | -110.40K | -160.17K | -14.11M | -59.59K | -1.70M | -11.48M | -11.23M | -936.03K | -1.64M | 2.80M | -2.23M | 14.81K | 41.67K | -31.78K |
| Income Before Tax | -18.43M | -48.81M | -10.29M | -8.53M | -2.71M | -1.00M | -2.38M | -16.14M | -549.82K | -2.20M | -12.30M | -13.45M | -3.51M | -4.56M | 2.23M | -2.87M | -984.81K | -833.71K | -178.94K |
| Income Before Tax Ratio | -153,575.00% | 0.00% | -1,904.94% | -599.33% | -649.59% | -91,835.01% | -317.25% | -7,444.24% | -804.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 30.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -204.00K | -229.80K | 0.00 | -88.06K | -1.32M | -1.09M | -278.89K | 0.00 | 0.00 | -18.10K | 0.00 | 0.00 | 0.00 |
| Net Income | -18.46M | -48.81M | -10.29M | -8.53M | -3.24M | -1.91M | -2.18M | -15.90M | -549.82K | -2.11M | -10.98M | -12.36M | -3.23M | -4.56M | 2.23M | -2.85M | -984.81K | -833.71K | -178.94K |
| Net Income Ratio | -153,825.00% | 0.00% | -1,904.94% | -599.33% | -776.62% | -175,041.70% | -291.24% | -7,336.20% | -804.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.14 | -3.17 | -0.03 | -0.03 | -0.02 | -0.01 | -0.04 | -0.50 | -0.04 | -0.17 | -1.08 | -1.34 | -0.50 | -1.07 | 0.90 | -1.72 | -0.73 | -1.18 | -0.37 |
| EPS Diluted | -1.14 | -3.17 | -0.03 | -0.03 | -0.02 | -0.01 | -0.04 | -0.50 | -0.04 | -0.17 | -1.08 | -1.34 | -0.50 | -0.73 | 0.51 | -1.72 | -0.73 | -1.13 | -0.37 |
| Weighted Avg Shares Out | 16.16M | 15.38M | 297.79M | 244.23M | 171.01M | 111.86M | 57.00M | 31.91M | 15.69M | 12.11M | 10.20M | 9.21M | 6.50M | 4.05M | 2.47M | 1.65M | 1.35M | 706.01K | 481.06K |
| Weighted Avg Shares Out (Dil) | 16.16M | 15.38M | 297.79M | 244.23M | 171.01M | 111.86M | 57.00M | 31.91M | 15.69M | 12.11M | 10.20M | 9.21M | 6.50M | 5.88M | 4.37M | 1.65M | 1.35M | 738.99K | 481.06K |
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)
Dallas, Texas--(Newsfile Corp. - May 1, 2024) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Potentially Transformative therapies for Generalized Anxiety Disorder (GAD)." This report explores the pervasive issue of GAD, a condition...
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation
MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investigational New Drug) meeting...
Clarion Clinics Open for Psychedelic-Assisted Treatments
Highlights: Clarion's Head of Psychiatry, Professor Suresh Sundram, has been approved by the TGA to prescribe MDMA for Post-traumatic Stress Disorder and psilocybin for Treatment-resistant Depression, alongside extensive psychotherapy. Clarion Clinics' built-for-purpose clinic in Melbourne is now open for treatment,...
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis
MELBOURNE, Australia and NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a pharmaceutical company developing novel medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies for unmet medical needs, is pleased to announce that...
Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences
Highlights: 72 patients treated at purpose-built facilities within Monash University, Melbourne, Australia. Topline results from the trial anticipated within current Q1 2024.
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
MELBOURNE, Australia and NEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that an independent Institutional Review Board (IRB)...
Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia
Highlights: Incannex subsidiary, Clarion Clinics, has received Human Research Ethics Committee (HREC) endorsement for administration of psychedelic-assisted therapies for TRD and PTSD. HREC approval is required for the administration of psychedelic drugs in Australia.
5 Biotech stocks tapping into unmet mental health treatment needs
Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are giving patients new hope for recovery and...
Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea
MELBOURNE, Australia and NEW YORK, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies for unmet medical needs, is pleased to provide...
These 3 Biotech Stocks More Than Doubled in November. Can They Fly Even Higher in 2024?
Korro Bio is working on an RNA-editing platform, and its stock price shot up 171% in November. Gyre Therapeutics is a commercial-stage drugmaker in China that could expand into the lucrative U.S. market.
Source: https://incomestatements.info
Category: Stock Reports